Skip to main content

Table 1 Population demographics including unique patient LAI new starts and LAI discontinuations; stratified by gender, age, province/region, and payer type. Reported as total number of events (n) and percentage (%)

From: Long-acting injectable antipsychotic (LAI) prescribing trends during COVID-19 restrictions in Canada: a retrospective observational study

LAI New Starts: January 2019 to December 2020

Number of Unique Patients by Epoch

Characteristic

All LAI New Starts

(n = 26,770)

COVID Awareness Period

(n = 4459)

Primary COVID Escalation Period

(n = 4518)

COVID Maintenance Period

(n = 4500)

Second COVID Escalation Period

(n = 4434)

Pre-COVID Comparator Period

(n = 4303)

Gender

 Women, n (%)

9504 (35.5)

1535 (34.4)

1636 (36.2)

1599 (35.5)

1560 (35.2)

1504 (35.0)

 Men, n (%)

17,266 (64.5)

2924 (65.6)

2882 (63.8)

2901 (64.5)

2874 (64.8)

2799 (65.0)

Age In Years

 18–35, n (%)

12,205 (45.6)

2073 (46.5)

2122 (47.0)

2101 (46.7)

2205 (49.7)

1890 (43.9)

 36–50, n (%)

8121 (30.3)

1334 (29.9)

1338 (29.6)

1370 (30.4)

1284 (29.0)

1369 (31.8)

 51–64, n (%)

4444 (16.6)

709 (15.9)

762 (16.9)

734 (16.3)

665 (15.0)

723 (16.8)

 65+, n (%)

2000 (7.5)

343 (7.7)

296 (6.6)

295 (6.6)

280 (6.3)

321 (7.5)

Province

 AB, n (%)

2410 (9.0)

381 (8.5)

439 (9.7)

422 (9.4)

413 (9.3)

380 (8.8)

 Atlantic CA, n (%)

1983 (7.4)

350 (7.8)

324 (7.2)

287 (6.4)

317 (7.1)

308 (7.2)

 BC, n (%)

2636 (9.8)

424 (9.5)

436 (9.7)

441 (9.8)

418 (9.4)

413 (9.6)

 MB, n (%)

537 (2.0)

97 (2.2)

88 (1.9)

98 (2.2)

93 (2.1)

104 (2.4)

 ON, n (%)

8214 (30.7)

1389 (31.2)

1428 (31.6)

1414 (31.4)

1410 (31.8)

1347 (31.3)

 QC, n (%)

10,166 (38.0)

1657 (37.2)

1669 (36.9)

1708 (38.0)

1651 (37.2)

1620 (37.6)

 SK, n (%)

824 (3.1)

161 (3.6)

134 (3.0)

130 (2.9)

132 (3.0)

131 (3.0)

Payer

 Cash / Unknown source, n (%)

1623 (6.1)

240 (5.4)

251 (5.6)

276 (6.1)

308 (6.9)

215 (5.0)

 Government, n (%)

21,528 (80.4)

3550 (79.6)

3619 (80.1)

3619 (80.4)

3550 (80.1)

3563 (82.8)

 Private, n (%)

3619 (13.5)

669 (15.0)

648 (14.3)

605 (13.4)

576 (13.0)

525 (12.2)

LAI Discontinuations: January 2019 to December 2020

Number of Unique Patients, by Epoch

Characteristic

All LAI Discontinuations

(n = 26,548)

COVID Awareness Period

(n = 4242)

Primary COVID Escalation Period

(n = 4507)

COVID Maintenance Period

(n = 4382)

Second COVID Escalation Period

(n = 4509)

Pre-COVID Comparator Period

(n = 4347)

Gender

 Women, n (%)

9331 (35.1)

1462 (34.5)

1575 (34.9)

1604 (36.6)

1546 (34.3)

1549 (35.6)

 Men, n (%)

17,217 (64.9)

2780 (65.5)

2932 (65.1)

2778 (63.4)

2963 (65.7)

2798 (64.4)

Age In Years

 18–35, n (%)

11,411 (43.0)

1851 (43.6)

1915 (42.5)

2041 (46.6)

2087 (46.3)

1879 (43.2)

 36–50, n (%)

8124 (30.6)

1293 (30.5)

1399 (31.0)

1301 (29.7)

1342 (29.8)

1340 (30.8)

 51–64, n (%)

4714 (17.8)

718 (16.9)

815 (18.1)

737 (16.8)

711 (15.8)

746 (17.2)

 65+, n (%)

2299 (8.7)

380 (9.0)

378 (8.4)

303 (6.9)

369 (8.2)

382 (8.8)

Province

 AB, n (%)

2457 (9.3)

393 (9.3)

398 (8.8)

425 (9.7)

394 (8.7)

442 (10.2)

 Atlantic CA, n (%)

1784 (6.7)

286 (6.7)

284 (6.3)

272 (6.2)

300 (6.7)

295 (6.8)

 BC, n (%)

2721 (10.2)

390 (9.2)

529 (11.7)

452 (10.3)

418 (9.3)

476 (11.0)

 MB, n (%)

556 (2.1)

92 (2.2)

126 (2.8)

105 (2.4)

92 (2.0)

110 (2.5)

 ON, n (%)

8242 (31.0)

1342 (31.6)

1456 (32.3)

1404 (32.0)

1445 (32.0)

1338 (30.8)

 QC, n (%)

10,003 (37.7)

1610 (38.0)

1594 (35.4)

1579 (36.0)

1716 (38.1)

1559 (35.9)

 SK, n (%)

785 (3.0)

129 (3.0)

120 (2.7)

145 (3.3)

144 (3.2)

127 (2.9)

Payer

 Cash / Unknown source, n (%)

1487 (5.6)

237 (5.6)

227 (5.0)

262 (6.0)

264 (5.9)

219 (5.0)

 Government, n (%)

21,785 (82.1)

3468 (81.8)

3716 (82.4)

3549 (81.0)

3656 (81.1)

3602 (82.9)

 Private, n (%)

3276 (12.3)

537 (12.7)

564 (12.5)

571 (13.0)

589 (13.1)

526 (12.1)

  1. To protect sensitive personal information, small cell sizes of 1–5 subjects were managed by grouping or excluding specific categories. *NB, NL, NS and PE have been combined into Atlantic Canada. The unique patient demographics are based on the earliest new start or discontinuation included in this study or in an epoch. LAI, long-acting injectable antipsychotic; AB, Alberta; BC, British Columbia; MB, Manitoba; ON, Ontario; QC, Quebec; SK, Saskatchewan